Synlogic (STU:MIN) Quality Rank


STU:MIN Synlogic Inc STU:MIN
30 GF Score
Price €3.63
GF Value €0.15
! 1 Warning Sign
View Full Analysis

What is Synlogic Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Synlogic Quality Rank Related Terms

STU:MIN
30GF Score
Synlogic Inc STU:MIN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Synlogic (STU:MIN) Overvalued in 2026?

Based on GuruFocus' analysis, Synlogic stock appears to be overvalued. The current stock price of €3.63 is trading 2320% above its estimated GF Value™ of €0.15.

Key valuation signals for STU:MIN:

  • Quality Rank:
  • GF Value™: €0.15 vs. price of €3.63 (2320% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Synlogic Business Description

Other Exchanges SYBX:USA0A8U:UK
Address PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
30GF Score

Get the complete analysis for STU:MIN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.63
Price
€0.15
GF Value